News Room

News

BeyondDx to Present Clinical Results of ‘ForeCheck LC’ for Early Lung Cancer Detection at ASCO 2025

2025-03-27 15:03:28

https://www.biotimes.co.kr/news/articleView.html?idxno=20498

BeyondDx to Present Clinical Results of ‘ForeCheck LC’ for Early Lung Cancer Detection at ASCO 2025

Blood biomarker analysis completed within just 150 minutes, offering speed and efficiency
Demonstrated sensitivity of 81.9% and specificity of 90.1% in early-stage (Stage 1/2) lung cancer


[BioTimes] BeyondDx, a company specializing in multi-integrated analysis solutions, announced on March 27 that it will present clinical study results of its early lung cancer diagnostic in-vitro device, ‘ForeCheck LC’, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this May.

확대이미지

‘ForeCheck LC’ is a blood-based diagnostic device leveraging BeyondDx’s proprietary multi-integrated analysis solution for early lung cancer detection. The device provides optimal diagnostic insights through a simple blood test and employs specific multi-biomarkers and machine learning algorithms to detect lung cancer, even in hard-to-identify Stage 1 and 2 cases. Notably, it can complete blood biomarker analysis and deliver results within just 150 minutes, emphasizing speed and efficiency.

 

At ASCO 2025, BeyondDx will unveil key findings from a clinical study conducted in collaboration with Professor Seok Ki Cho’s team at Seoul National University Bundang Hospital’s Department of Thoracic Surgery. The study evaluated the performance of ‘ForeCheck LC’ in a cohort of approximately 1,800 lung cancer patients (Stages 1–4). The results confirmed a sensitivity of 81.9% and specificity of 90.1% for early-stage (Stage 1/2) lung cancer, underscoring its potential as a blood-based alternative to low-dose computed tomography (LDCT), which has certain limitations.

 

A BeyondDx representative stated, “ForeCheck LC is an innovative early lung cancer diagnostic solution that ensures high compliance among high-risk, asymptomatic individuals. With its rapid, convenient, and cost-effective approach, it presents a promising alternative to conventional imaging tests.” The company plans to initiate pivotal clinical trials in mid-2025 for regulatory approval in South Korea and is actively engaging with potential partners to accelerate market entry.

 

 

[BioTimes | Reporter: Jisoo Kim] news@biotimes.co.kr